Abstract 206P
Background
Immune checkpoint inhibitorrelated thrombocytopenia (ICIRT) or targeted therapyrelated thrombocytopenia (TTRT) is one of the common adverse reactions to antineoplastic drugs. Objective: To explore the clinical efficacy and safety of avatrombopag for ICIRT or TTRT in patients with hepatocellular carcinoma (HCC).
Methods
This prospective, multicenter, single-arm trial enrolled ICIRT or TTRT in patients with HCC in two centers from June 2022 to February 2024. The primary endpoint was the proportion of responders (patients with platelet count ≥75×109/L or increased ≥25×109/L or increased by ≥100% from the baseline and not received rescue therapy for bleeding) before the next targeted/immunotherapy cycle (21 days).
Results
A total of 52 patients were included. The number of responders who met the primary endpoint (any criteria) was 46 (86.54%), of which 36 (69.23%) patients met PLT counts ≥75×109/L, 37 (71.15%) patients met PLT counts increased ≥25×109/L and 31 (59.62%) patients met PLT counts increased by ≥100% from the baseline. There were no serious AEs occurring during treatment and no patients discontinuing treatment due to AEs. There were also no bleeding-related or thrombosis-related AEs. The most common AEs were nausea (n=5, 9.62%), pyrexia (n=5, 9.62%), abdominal pain (n= 4, 7.69%), fatigue (n=3, 5.77%), headache (n=2, 3.85%) and peripheral edema (n=1, 1.92%).
Conclusions
Avatrombopag is safe and effective in the treatment of ICIRT or TTRT in patients with HCC.
Clinical trial identification
The study was registered at https://www.chictr.org.cn/ (registration number: ChiCTR2200065912).
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The national natural science foundation of China.
Disclosure
All authors have declared no conflicts of interest.